Results from TCGA showed that MTCH2 expression was positively correlated with glioma grade, and high MTCH2 expression tended to be associated with GBM subtype (Fig. 2a, b), coinciding with the fact that MTCH2 correlates with poor patient survival. The gene discussed is MTCH2; the disease is central nervous system cancer.